VistaGen Therapeutics Inc (VTGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VistaGen Therapeutics Inc (VTGN) has a cash flow conversion efficiency ratio of -0.346x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.63 Million) by net assets ($50.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VistaGen Therapeutics Inc (VTGN) defensive interval to measure how many days the company can operate on defensive assets alone.
VistaGen Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how VistaGen Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
VistaGen Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VistaGen Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Siili Solutions Oyj
HE:SIILI
|
-0.093x |
|
Gabungan AQRS Bhd
KLSE:5226
|
-0.112x |
|
Upland Software Inc
NASDAQ:UPLD
|
0.072x |
|
Maternus-Kliniken Aktiengesellschaft
F:MAK
|
0.026x |
|
Palatin Technologies, Inc. Common Stock
NASDAQ:PTN
|
-0.417x |
|
Earlypay Ltd
AU:EPY
|
0.039x |
|
Asset Vision Co Ltd
AU:ASV
|
0.089x |
|
Sidiz Inc
KO:134790
|
-0.015x |
Annual Cash Flow Conversion Efficiency for VistaGen Therapeutics Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of VistaGen Therapeutics Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see VistaGen Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $70.39 Million | $-42.10 Million | -0.598x | -164.79% |
| 2024-03-31 | $114.29 Million | $-25.81 Million | -0.226x | +94.51% |
| 2023-03-31 | $12.08 Million | $-49.72 Million | -4.115x | -488.50% |
| 2022-03-31 | $64.72 Million | $-45.26 Million | -0.699x | -432.75% |
| 2021-03-31 | $91.98 Million | $-12.07 Million | -0.131x | -104.77% |
| 2020-03-31 | $-5.73 Million | $-15.76 Million | 2.750x | +233.94% |
| 2019-03-31 | $7.08 Million | $-14.53 Million | -2.053x | -56.78% |
| 2018-03-31 | $6.92 Million | $-9.06 Million | -1.310x | +88.89% |
| 2017-03-31 | $615.80K | $-7.26 Million | -11.793x | -830.16% |
| 2016-03-31 | $-2.98 Million | $-4.81 Million | 1.615x | +1098.27% |
| 2015-03-31 | $-20.54 Million | $-2.77 Million | 0.135x | -18.85% |
| 2014-03-31 | $-12.80 Million | $-2.13 Million | 0.166x | -39.78% |
| 2013-03-31 | $-12.56 Million | $-3.46 Million | 0.276x | -55.87% |
| 2012-03-31 | $-5.71 Million | $-3.57 Million | 0.625x | -90.91% |
| 2011-03-31 | $-1.00K | $-6.88K | 6.878x | -96.25% |
| 2010-03-31 | $-124.00 | $-22.76K | 183.516x | +26003.82% |
| 2009-03-31 | $20.37K | $-14.43K | -0.708x | -102.13% |
| 2008-03-31 | $-145.00 | $-4.81K | 33.200x | -- |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more